Active Investment in the Medical Business and Expansion of Growth Areas
First written in FY2016. 27 of 39 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2026.
0 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「BioProtect is an Israel-based medical device manufacturer developing implant technology to protect healthy tissue during radiation therapy and surgery.」
On 1 June 2026, the company acquired 100% of BioProtect Ltd. and expanded its product portfolio in urology and adjacent cancer treatment fields, including biodegradable balloon rectal spacers for prostate cancer. The transaction value was US$270 million. - FY2026-H1AdvancedAnnual report
「The group plans to invest in Swan EndoSurgical jointly with Revival to develop new endoluminal robotic products.」
For endoluminal robot development, the company initially invested 45% and US$29.3 million in Swan EndoSurgical jointly with a fund of Revival Healthcare Capital. Depending on the achievement of milestones over multiple fiscal years, the company may make additional investments of up to US$206 million over the next 6 years. - FY2025AdvancedAnnual report
「On 14 January 2025, the company acquired Sur Medical SpA's Olympus product distribution business through its consolidated subsidiary Olympus Latin America, Inc.」
The company completed the acquisition of the distribution business to directly expand sales of its own products and business strategy in Chile, improve operational efficiency and strengthen customer service. - FY2025AdvancedAnnual report
「Key achievements during the period included launching the VISERA S outpatient imaging platform in Japan, Europe and parts of Asia-Oceania; launching a 4K camera head for urological endoscopy in Europe; expanding the sales regions for the iTind minimally invasive treatment device for BPH; and launching a new design in the POWERSEAL high-frequency sealing device series.」
The company advanced growth initiatives in therapeutic devices, including regional launches of new products, expansion of iTind sales regions and the launch of a new POWERSEAL design. - FY2025AdvancedAnnual report
「In the therapeutic devices business, all 3 priority areas—gastroenterology therapeutic devices, urology and respiratory medicine—recorded positive growth, led by North America and Europe.」
All 3 priority areas—gastroenterology therapeutic devices, urology and respiratory medicine—recorded positive growth as growth investments in the therapeutic devices business. - FY2025-H1AdvancedAnnual report
「In the therapeutic devices business, all 3 priority areas—gastroenterology therapeutic devices, urology and respiratory medicine—recorded positive growth, led by North America and Europe.」
All 3 priority areas—gastroenterology therapeutic devices, urology and respiratory medicine—recorded positive growth, led by North America and Europe, as growth investments in the therapeutic devices business. - FY2024AdvancedAnnual report
「Flagship gastrointestinal endoscopy system EVIS X1: launched in Europe, Asia and Japan in the fiscal year ended March 2021, and in the United States and China in the fiscal year ended March 2024. The company aims to further expand sales.」
The company expanded the launch regions for EVIS X1 to the United States and China and proceeded with preparations for single-use endoscopes and local production in China. At the same time, it discontinued the manufacture and sale of VMT products and terminated its agreement with Taewoong Medical. - FY2024-Q3AdvancedAnnual report
「By adding Taewoong Medical's medical devices to its product portfolio, the company will provide more comprehensive and diverse solutions in its priority gastroenterology business and help improve patient outcomes.」
As an investment in growth areas of gastroenterology, the company acquired 99.6% of the voting shares of Taewoong Medical on 24 January 2024. The transaction value was US$370 million, expanding its gastroenterology product portfolio. - FY2024-Q2WorsenedAnnual report
「The company recorded ¥49,586 million under "Other expenses" as a loss related to the discontinuation of the manufacture and sale of Veran Medical Technologies, Inc.'s electromagnetic navigation system. This comprised an inventory write-down of ¥2,278 million, an impairment loss on fixed assets of ¥40,736 million (Note), and ¥6,572 million in costs associated with the voluntary product recall and other items.」
In response to non-compliance with quality standards and changing customer needs, the company decided on 6 September 2023 to discontinue the manufacture and sale of products made by VMT, which it had acquired as part of its growth investments in medical and therapeutic devices. It recorded related losses of ¥49,586 million, marking a clear setback for its previous growth initiatives. - FY2024-Q1AdvancedAnnual report
「In gastrointestinal endoscopy, sales in China recovered from the impact of lockdowns in Shanghai and other cities in the same period of the previous year, while sales also increased in Asia-Oceania and Japan, resulting in year-on-year growth. In surgical endoscopy, sales increased in Asia-Oceania and Europe following the launch of the VISERA ELITEⅢ surgical endoscopy system, resulting in year-on-year growth in all regions.」
Reports recovery in gastrointestinal endoscopy sales in China, the launch of VISERA ELITEⅢ and year-on-year growth in surgical endoscopy in all regions as growth investments in the medical business. - FY2023AdvancedAnnual report
「We will continue to focus on the 3 areas in which we hold leading positions—gastroenterology, urology and respiratory medicine—and provide solutions suited to patients' care pathways through advanced imaging, precision treatment and high-value-added solutions.」
The company identified gastroenterology, urology and respiratory medicine as the 3 priority areas for growth investment and set out a specific approach combining imaging, treatment and solutions. - FY2023-Q3AdvancedAnnual report
「In urology, performance was strong, particularly in North America and Europe, and sales of resection electrodes for BPH and the SOLTIVE SuperPulsed Laser System for urinary stones expanded steadily.」
Sales of BPH resection electrodes and SOLTIVE expanded steadily in North America and Europe as growth investments in the therapeutic devices business. - FY2023-Q2AdvancedAnnual report
「In urology, performance was strong, particularly in North America and Europe, and sales of resection electrodes for BPH and the SOLTIVE SuperPulsed Laser System for urinary stones expanded steadily.」
Sales of BPH products and SOLTIVE continued to expand in North America and Europe as growth investments in therapeutic devices. - FY2023-Q1RestatedAnnual report
「In urology, performance was strong, particularly in North America and Europe, and expanded sales of resection electrodes for BPH and the SOLTIVE SuperPulsed Laser System for urinary stones contributed to the performance.」
Reports that expanded sales of BPH products and SOLTIVE continued to deliver results as growth areas in the therapeutic devices business. - FY2022-Q2AdvancedAnnual report
「Performance was particularly strong in North America, where procedure volumes were recovering toward pre-pandemic levels. Expanded sales of resection electrodes for BPH and the SOLTIVE SuperPulsed Laser System for urinary stones contributed to the performance.」
With procedure volumes recovering in North America, growth investments in the therapeutic devices business began to bear fruit through expanded sales of BPH products and SOLTIVE. - FY2022-Q1AdvancedAnnual report
「By adding Medi-Tate's minimally invasive treatment devices for BPH to its product portfolio, the company will help expand the use of minimally invasive treatments for diverse prostate diseases, improve patients' quality of life and further strengthen its competitiveness in urology.」
On 27 May 2021, the company acquired additional shares in Medi-Tate Ltd., making it a wholly owned subsidiary, and added minimally invasive treatment devices for BPH to its product portfolio. - FY2021RaisedAnnual report
「Specifically, we aim to achieve average annual growth of 8% in the therapeutic devices business over the 3 years from the fiscal year ending March 2021 through the fiscal year ending March 2023 by implementing the following initiatives and others.」
In addition to the existing target of average annual growth of 6% in the endoscopy business, the company set a 3-year target of average annual growth of 8% and specific initiatives for the therapeutic devices business. - FY2021-Q3AdvancedAnnual report
「Through this acquisition, the company will strengthen its portfolio of innovative products that improve patients' quality of life and are used in ligament reconstruction, ankle fusion and trauma surgery. It will also expand the group's sales channels and grow the business by marketing its orthopedic products through FH ORTHO's global distribution network and selling some of FH ORTHO's core products in Japan.」
Following the acquisition of Arc Medical Design, the company acquired 100% of FH ORTHO on 2 November 2020 and 100% of Veran Medical Technologies on 29 December 2020. It is expanding its orthopedic and respiratory product portfolios, sales channels and presence in minimally invasive treatment. - FY2021-Q2AdvancedAnnual report
「To further strengthen its core competencies in early diagnosis and minimally invasive treatment, the company is working to expand its gastrointestinal disease treatment device lineup and develop devices to support the diagnosis and treatment of colorectal cancer, not only through in-house development but also by acquiring suitable partners. Through this acquisition, the company acquired all rights to Arc Medical Design's innovative products.」
On 7 August 2020, the company acquired 100% of Arc Medical Design Limited and moved to a structure responsible for the design, manufacture, sales and business strategy of the ENDOCUFF product range. - FY2021-Q1AdvancedAnnual report
「Although the flagship EVIS X1 endoscopy system was launched in Europe and parts of Asia in April 2020, sales in the endoscopy business declined as promotional activities were constrained by restrictions on visits to customers such as medical institutions and the postponement or cancellation of business meetings due to the COVID-19 pandemic. In addition, the number of procedures declined after medical societies recommended postponing or cancelling gastrointestinal endoscopic examinations.」
As a growth investment in the endoscopy business, EVIS X1 was launched in Europe and parts of Asia. Sales activities were affected by the pandemic. - FY2020RaisedAnnual report
「Specifically, we aim to achieve average annual growth of 6% in the endoscopy business over the next 3 years by implementing the following initiatives and others.」
The company specified initiatives including single-use products and sales and service models in the endoscopy business as growth investments in the medical business, together with a target of average annual growth of 6% over the next 3 years. - FY2020-Q3AdvancedAnnual report
「Sales remained strong for new flexible ureteroscopes, new flexible endoscopes for otolaryngology and single-use endoscopic therapeutic devices used in the diagnosis and treatment of the pancreatic and biliary ducts and other areas. In addition, sales continued to grow for single-use THUNDERBEAT products and EBUS therapeutic devices in the respiratory business, and revenue from the therapeutic devices business increased.」
Specifically reports progress in sales of new flexible ureteroscopes, flexible endoscopes for otolaryngology, single-use therapeutic devices, THUNDERBEAT and EBUS therapeutic devices in the therapeutic devices business. - FY2020-Q2AdvancedAnnual report
「Sales remained strong for new flexible ureteroscopes and single-use endoscopic therapeutic devices used in endoscopic diagnosis and treatment of the pancreatic and biliary ducts and other areas. In addition, sales continued to grow for single-use THUNDERBEAT products, and revenue from the therapeutic devices business increased.」
Reports progress in sales of new flexible ureteroscopes, single-use therapeutic devices and single-use THUNDERBEAT products in the therapeutic devices business. - FY2020-Q1RestatedAnnual report
「Sales of single-use endoscopic therapeutic devices used in endoscopic diagnosis and treatment of the pancreatic and biliary ducts and other areas remained strong. In addition, sales continued to grow for single-use THUNDERBEAT products, and revenue from the therapeutic devices business increased.」
Reconfirms strong sales of single-use therapeutic devices and single-use THUNDERBEAT products. - FY2019-Q3RestatedAnnual report
「In the surgical field, the new VISERA ELITE Ⅱ surgical endoscopy system performed well, while sales continued to grow for THUNDERBEAT, an integrated energy device combining bipolar radiofrequency and ultrasonic energy. In the therapeutic devices field, sales of single-use products used in endoscopic diagnosis and treatment of the pancreatic and biliary ducts and other areas were strong.」
Reconfirms strong sales of VISERA ELITE Ⅱ and THUNDERBEAT in surgery and single-use products in therapeutic devices. - FY2019-Q2RestatedAnnual report
「In the surgical field, the new VISERA ELITE Ⅱ surgical endoscopy system performed well, while sales continued to grow for THUNDERBEAT, an integrated energy device combining bipolar radiofrequency and ultrasonic energy. In the therapeutic devices field, sales of single-use products used in endoscopic diagnosis and treatment of the pancreatic and biliary ducts and other areas were strong.」
Reconfirms strong sales of VISERA ELITE Ⅱ and THUNDERBEAT in surgery and single-use products in the therapeutic devices field. - FY2019-Q1AdvancedAnnual report
「In the surgical field, the new VISERA ELITE Ⅱ surgical endoscopy system performed well, while sales continued to grow for THUNDERBEAT, an integrated energy device combining bipolar radiofrequency and ultrasonic energy.」
Sales of the new VISERA ELITE Ⅱ remained strong in the surgical field, and growth in THUNDERBEAT sales continued. - FY2018AdvancedAnnual report
「In the medical business, the company expanded its workforce and strengthened its quality and regulatory functions. In surgery, an area expected to deliver substantial growth under 16CSP, it fully launched new products in Japan and Europe. It also acquired U.S.-based Image Stream Medical to strengthen the operating-room systems integration identified as a key strategic priority, steadily implementing initiatives for future growth.」
Identifies expansion of the medical business workforce, quality and regulatory initiatives, new product launches and the acquisition of ISM as specific growth investments. - FY2018-Q3RestatedAnnual report
「In the surgical field, sales continued to grow for surgical endoscopy systems equipped with 4K technology, 3D endoscopy systems and THUNDERBEAT, an integrated energy device combining bipolar radiofrequency and ultrasonic energy. In the therapeutic devices field, sales were strong for disposable guidewires such as VisiGlide 2, used in endoscopic diagnosis and treatment of the pancreatic and biliary ducts and other areas.」
Continues to report progress in sales of 4K and 3D endoscopes, THUNDERBEAT and VisiGlide 2 in the surgical and therapeutic devices fields. - FY2018-Q2RestatedAnnual report
「In the surgical field, sales continued to grow for surgical endoscopy systems equipped with 4K technology, 3D endoscopy systems and THUNDERBEAT, an integrated energy device combining bipolar radiofrequency and ultrasonic energy. In the therapeutic devices field, sales were strong for disposable guidewires such as VisiGlide 2, used in endoscopic diagnosis and treatment of the pancreatic and biliary ducts and other areas.」
Continues to report progress in sales of 4K and 3D endoscopes, THUNDERBEAT and VisiGlide 2 in the growth areas of surgery and therapeutic devices. - FY2018-Q1RestatedAnnual report
「In surgery, the 4K surgical endoscopy system and 3D endoscopy system performed steadily, while sales of THUNDERBEAT, an integrated bipolar radiofrequency and ultrasonic energy device, continued to grow. In therapeutic devices, sales were strong for products including the VisiGlide 2 disposable guidewire, used in endoscopic diagnosis and treatment of the pancreatic and bile ducts.」
Continues to report progress in sales of 4K and 3D endoscopes, THUNDERBEAT and VisiGlide 2 in the surgical and therapeutic devices fields. - FY2017AdvancedAnnual report
「In the medical business, the company expanded its workforce as needed to strengthen its production and maintenance structures and advanced quality and regulatory compliance initiatives, while also progressing the development of major new products in surgery.」
It specifically describes growth investment in the medical business, including expanding production and maintenance staff, strengthening quality and regulatory compliance, and developing major new surgical products. - FY2017-Q3RestatedAnnual report
「In gastrointestinal endoscopy, sales of the core endoscopy systems EVIS EXERA Ⅲ (EVIS EXERA Three) and EVIS LUCERA ELITE (EVIS LUCERA Elite) both remained strong. In surgery, the integrated endoscopy video system VISERA ELITE (VISERA Elite), which supports endoscopic surgery, and the 3D endoscopy system performed steadily, while sales of THUNDERBEAT, an integrated bipolar radiofrequency and ultrasonic energy device, continued to grow. In therapeutic devices, sales were strong for products including the VisiGlide 2 disposable guidewire, used in endoscopic diagnosis and treatment of the pancreatic and bile ducts.」
It reconfirms strong sales and continued growth of existing products across gastrointestinal endoscopy, surgery and therapeutic devices. - FY2017-Q2AdvancedAnnual report
「In gastrointestinal endoscopy, sales of the core endoscopy systems EVIS EXERA Ⅲ (EVIS EXERA Three) and EVIS LUCERA ELITE (EVIS LUCERA Elite) both remained strong. In surgery, the integrated endoscopy video system VISERA ELITE (VISERA Elite), which supports endoscopic surgery, and the 3D endoscopy system performed steadily, while sales of THUNDERBEAT, an integrated bipolar radiofrequency and ultrasonic energy device, continued to grow. In therapeutic devices, sales were strong for products including the new EZ Shot 3 Plus disposable aspiration biopsy needle (EZ Shot Three Plus), used for endoscopic ultrasound-guided fine-needle aspiration.」
It specifically describes strong sales of existing products and progress in sales of new products across the endoscopy, surgery and therapeutic-device growth areas. - FY2016First statedAnnual report
「In the core gastrointestinal endoscopy field, strong sales continued in Japan and overseas, while sales also grew in surgery and therapeutic devices as a result of active growth investments, including efforts to strengthen sales.」
It describes sales-force expansion and growth investment as means of expanding the surgery and therapeutic-device businesses.